Company profile: Sprint Bioscience
1.1 - Company Overview
Company description
- Provider of a fragment-based, modular gene-to-lead drug discovery platform covering protein expression/purification, fragment screening, X-ray crystallography, and fragment-to-lead expansion. Develops small-molecule candidates from idea to preclinical stage for licensing. Programs: TREX1 (DISA), VRK1 (VADA, licensed to Day One Biopharmaceuticals), NNMT (NIMA). Based in Stockholm, Sweden.
Products and services
- Fragment-Based Drug Discovery (FBDD) Platform: Sprint Bioscience delivers a modular gene-to-lead platform integrating protein expression and purification, fragment screening, X-ray crystallography, and expansion of fragments into a patented lead series
- Small-Molecule Drug Candidates: Sprint Bioscience engineers preclinical-grade small-molecule drug candidates from idea to a preclinical drug project, ready for licensing to the international pharma market
- VADA Program: Sprint Bioscience advances the oncology-focused VADA program targeting VRK1, licensed to Day One Biopharmaceuticals, concentrating on preclinical research and development for cancer therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sprint Bioscience
Bruker
HQ: United States
Website
- Description: Provider of analytical and medical instruments covering NMR, ESR, FT-IR and X-ray spectroscopy. MALDI Imaging to visualize molecular distribution in tissue sections; neofleX MALDI-TOF/TOF benchtop MS for protein and peptide analysis; Q6 NEWTON optical emission spectrometer for precise metal and alloy composition; BEAM FT-NIR for real-time process control of solid and semi-solid materials; and Dektak Pro profilometer for semiconductor surfaces.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bruker company profile →
LEAP Technologies
HQ: Australia
Website
- Description: Provider of micro dispensing, PAL accessories, support, and repair services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAP Technologies company profile →
BioAffinity Technologies
HQ: United States
Website
- Description: Provider of non-invasive, early-stage cancer diagnostics, including CyPath® Lung, a sputum-based lung cancer test analyzed via flow cytometry and machine learning. Through Precision Pathology Laboratory Services, offers laboratory services and provides CyPath® Lung as a Laboratory Developed Test. Also conducts R&D to expand porphyrin-based platform technologies for targeted cancer diagnostics and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioAffinity Technologies company profile →
Tissue Solutions
HQ: United Kingdom
Website
- Description: Provider of rapid, ethically compliant access to high-quality biospecimens via a virtual biobank offering a single point of access to diseased and normal human biomaterials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tissue Solutions company profile →
Native Antigen
HQ: United Kingdom
Website
- Description: Provider of native and recombinant viral and bacterial antigens, antibodies and immunoassays, specialising in their development and manufacture. Antigens are used by leading pharmaceutical companies and IVD manufacturers in vaccine research and serology, where proper folding and glycosylation are vital.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Native Antigen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sprint Bioscience
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sprint Bioscience
2.2 - Growth funds investing in similar companies to Sprint Bioscience
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sprint Bioscience
4.2 - Public trading comparable groups for Sprint Bioscience
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →